| dc.creator |
Akar, Servet |
|
| dc.creator |
Yazısız, Veli |
|
| dc.creator |
Kasifoglu, Timucin |
|
| dc.creator |
Yilmaz, Sema |
|
| dc.creator |
Özisler, Cem |
|
| dc.creator |
AYAN, GİZEM |
|
| dc.creator |
Ersozlu, Emine Duygu |
|
| dc.creator |
Bayindir, Ozun |
|
| dc.creator |
KILIÇ, LEVENT |
|
| dc.creator |
DALKILIÇ, HÜSEYİN EDİZ |
|
| dc.creator |
Esmen, Serpil Ergulu |
|
| dc.creator |
DOĞRU, Atalay |
|
| dc.creator |
Omma, Ahmet |
|
| dc.creator |
Duruoz, Tuncay |
|
| dc.creator |
Küçüksahin, Orhan |
|
| dc.creator |
Yildiz, Fatih |
|
| dc.creator |
Kimyon, Gezmis |
|
| dc.creator |
Erden, Abdulsamet |
|
| dc.creator |
Aydin, Sibel Zehra |
|
| dc.creator |
Tarhan, Emine Figen |
|
| dc.creator |
Bakirci, Sibel |
|
| dc.creator |
Günal, Esen Kasapoglu |
|
| dc.creator |
Cetin, Gözde Yildirim |
|
| dc.creator |
Gonullu, Emel |
|
| dc.creator |
Aksu, Kenan |
|
| dc.creator |
Tufan, Abdurrahman |
|
| dc.creator |
Pehlevan, Seval |
|
| dc.creator |
Solmaz, Dilek |
|
| dc.creator |
Cinar, Muhammed |
|
| dc.creator |
Kalyoncu, Umut |
|
| dc.date |
2023-02-01T00:00:00Z |
|
| dc.date.accessioned |
2024-08-26T12:08:18Z |
|
| dc.date.available |
2024-08-26T12:08:18Z |
|
| dc.identifier |
10dd9cec-9e2d-4995-9582-955ae30f3e8d |
|
| dc.identifier |
10.1007/s10067-022-06492-6 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/10dd9cec-9e2d-4995-9582-955ae30f3e8d/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/98747 |
|
| dc.description |
© 2023, The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).Background: This study aimed to assess the mortality of PsA before and during the COVID-19 pandemic. Methods: From the prospective, multicenter PsART-ID (Psoriatic Arthritis Registry-International Database), patients from Turkey were analyzed by linking the registry to the Turkish Cause of Death Registry. The outcome of interest was death from any cause, pre-pandemic (since the onset of registry—March 2014–March 2020), and during the pandemic (March 2020–May 2021). The crude mortality rate and standardized mortality ratio (SMR) were determined. Results: There were 1216 PsA patients with a follow-up of 7500 patient-years. Overall, 46 deaths (26 males) were observed. In the pre-pandemic period, SMR for PsA vs the general population was 0.95 (0.61–1.49), being higher in males [1.56 (0.92–2.63)] than females [0.62 (0.33–1.17)]. The crude mortality rate in PsA doubled during the pandemic (pre-pandemic crude mortality rate: 5.07 vs 10.76 during the pandemic) with a higher increase in females (2.9 vs 8.72) than males (9.07 vs 14.73). Conclusion: The mortality in PsA was found similar to the general population in the pre-pandemic era. The mortality rates in PsA doubled during the pandemic. Whether PsA patients have more risk of mortality than the general population due to COVID-19 needs further studies.Key Points• Decrease in mortality in PsA might be expected with the more effective treatment options and better disease control.• A crude mortality rate is comparable to the general population and not increased until the pandemic.• Currently, there is a 2-fold increase in crude mortality rate possibly due to the COVID-19. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Mortality in psoriatic arthritis patients, changes over time, and the impact of COVID-19: results from a multicenter Psoriatic Arthritis Registry (PsART-ID) |
|
| dc.type |
info:eu-repo/semantics/article |
|